Viriom Announces Appointment of New Scientific Advisory Board Member
"Dr. Hammond's knowledge and experience in the fields of virology and infectious diseases will serve as an invaluable addition to Viriom's efforts in developing innovative HIV treatments and will enrich its Scientific Advisory Board with a unique perspective," said Nikolay Savchuk, PhD, Chairman of Viriom's Scientific Advisory Board. "We believe that Dr. Hammond's clinical expertise as well as experience in drug development and regulatory affairs will help support Viriom's quest to provide more effective solutions for HIV patients."
"Viriom's innovative research aims at bringing to live the next generation of antiviral treatments that will not only be effective but also affordable, and I am delighted to become a part of the company's renown team and contribute to advancing its novel therapies," said Janet Hammond. After receiving her MD and PhD from the University of Cape Town, South Africa, Dr. Hammond has been an exceptionally active contributor to infectious disease therapies, leading the submission of three New Drug Applications (NDA) and Marketing Authorization Applications, more than ten supplemental NDAs, and more than ten Investigational New Drug (IND) applications in the past thirteen years.
Viriom's Scientific Advisory Board members are prominent medical practitioners and scientists with extensive experience in virology and infectious diseases, working together to provide scientific and clinical advice on the development of novel and affordable therapies against life threatening infections including HIV and hepatitis B.
Viriom Inc. is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life threatening infections such as HIV and HBV. Viriom holds exclusive worldwide rights from F. Hoffmann-La Roche for VM1500, which it is presently developing as an oral AIDS treatment (Elpida® elpivirine) for active HIV infections; and as innovative longer-acting formulations of elpivirine for PrEP and PEP in high-risk patient populations. Viriom is also developing a proprietary therapeutic for chronic HBV infections. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries. For more information, please visit www.viriom.com.